Hypothesis: Dual inhibition of CB1R & iNOS as a potential novel approach to the pharmacological management of acute & long COVID‐19, 2021, Cinar et al

Abstract

COVID‐19 (SARS‐CoV‐2) causes multiple inflammatory complications, resulting not only in severe lung inflammation but also in harm to other organs. While current focus is on the management of acute COVID‐19, there is growing concern about long term effects of COVID‐19 (Long Covid), such as fibroproliferative changes in lung, heart and kidney. Therefore, identifying therapeutic modalities is needed not only for the management of acute COVID‐19 but also for preventing Long Covid, which could mitigate long lasting health burden and economic costs in addition to saving lives. COVID‐19 induces pathologic changes through multiple pathways, which could be targeted simultaneously for optimal effect. Here, we discuss the potential pathologic function of increased activity of the endocannabinoid (EC)/CB1 receptor (CB1R) system and inducible NO synthase (iNOS). We advocate a polypharmacology approach wherein a single chemical entity simultaneously engages CB1R and iNOS for inhibition as a potential therapeutic strategy for COVID‐19 related health complications.

Open access, https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bph.15461

 

Inhibition of iNOS in vivo is probably still not possible, I guess, though.